Document Detail

Statins and Lipid-Lowering Strategies in PD.
MedLine Citation:
PMID:  22652725     Owner:  NLM     Status:  In-Data-Review    
Both traditional and nontraditional cardiovascular risk factors are considered to contribute to the high prevalence of cardiovascular disease (CVD) in peritoneal dialysis (PD) patients, and CVD is a major cause of both morbidity and mortality in this patient population. Among traditional risk factors, lipid disturbances are very common in patients with chronic renal failure and PD patients have in general, compared to hemodialysis (HD) and nondialyzed patients, an even more atherogenic lipid profile. The pathogenesis of the lipid disturbances in PD patients is not completely understood, but both the protein loss in the dialysate, and the glucose absorption from the dialysate may contribute to these alterations. Hydroxymethylglutaryl coenzyme A reductase inhibitors, more commonly known as statins, are effective to reduce low density cholesterol levels in PD patients and have few side effects. The use of statins is associated with reduced mortality in PD patients, but so far no large randomized controlled trial has been performed concerning the effects on clinical outcome in PD patients (except for the fact that 496 patients in the SHARP trial were treated with PD). In addition, except from their lipid lowering effects, statins also have pleiotropic effects, independent of their lipid lowering effect, that theoretically have beneficial effects on the peritoneal membrane remodeling. Use of alternative osmotic agents as well as nutritional interventions has also been reported to improve the lipid profilein PD patients.
Olof Heimbürger
Related Documents :
14962655 - Ancillary lung parenchymal findings at spiral ct scanning in pulmonary embolism. relati...
9929765 - Initial clinical experience with perducer device: promising new tool in the diagnosis a...
19522425 - Bronchoalveolar lavage impact in sarcoidosis: study of 40 cases.
3566675 - Sarcoidosis in children.
15352145 - Characteristics of the gpcog, a screening tool for cognitive impairment.
7828285 - The safety of intracoronary ultrasound. a multicenter survey of 2207 examinations.
Publication Detail:
Type:  Journal Article     Date:  2012-05-25
Journal Detail:
Title:  Contributions to nephrology     Volume:  178     ISSN:  1662-2782     ISO Abbreviation:  Contrib Nephrol     Publication Date:  2012  
Date Detail:
Created Date:  2012-06-01     Completed Date:  -     Revised Date:  -    
Medline Journal Info:
Nlm Unique ID:  7513582     Medline TA:  Contrib Nephrol     Country:  Switzerland    
Other Details:
Languages:  eng     Pagination:  106-10     Citation Subset:  IM    
Copyright Information:
Copyright © 2012 S. Karger AG, Basel.
Division of Renal Medicine, Department of Clinical Science, Intervention and Technology, Karolinska Institutet, Karolinska University Hospital, Stockholm, Sweden.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  Lipid disorders in uremia and dialysis.
Next Document:  Statin therapy is associated with decreased small, dense low-density lipoprotein levels in patients ...